EMA Authorised: Methylthioninium chloride Proveblue (methylthioninium chloride) — Provepharm SAS

View source ↗

Summary

EMA authorised Proveblue (methylthioninium chloride) for the treatment of methemoglobinemia, with Provepharm SAS as the marketing authorisation holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Methemoglobinemia

Drugs mentioned

• Proveblue (methylthioninium chloride)

Snippet

Status: Authorised. Therapeutic area: Methemoglobinemia. MAH: Provepharm SAS. Decision date: 02/10/2025